Analysis of  gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no  amplification by unknown
Hanna et al. SpringerPlus  (2015) 4:439 
DOI 10.1186/s40064-015-1235-9
RESEARCH
Analysis of ALK gene in 133 patients 
with breast cancer revealed polysomy 
of chromosome 2 and no ALK amplification
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Abstract 
ALK has emerged as a novel tumorigenic factor in several epithelial human cancers. Crizotinib, an ALK tyrosine kinase 
inhibitor, is currently approved to treat lung cancer patients exhibiting ALK gene rearrangements. Our goal was to 
determine the incidence of ALK aberrations in relation to different breast cancer types. Tissue micro-arrays were con-
structed of ER+/PR±/HER2− (n = 37), ER−/PR−/HER2+ (n = 15), ER−/PR−/HER2− (n = 61) and ER+/PR+/HER2+ 
(n = 20) breast cancers; including 13 inflammatory breast carcinomas. FISH was performed using ALK break-apart and 
chromosome 2 centromere enumeration probes (CEP2). Neither ALK rearrangements nor amplification were identi-
fied in the 133 breast cancer cases evaluated. However, copy number gains (CNG) of ALK were identified in 82 of 133 
patients (62 %). The CEP2 analysis revealed polysomy of chromosome 2 in all HCNG and LCNG cases, indicating the 
CNG of ALK are due to polysomy of chromosome 2, rather than true amplification of ALK. To conclude, we observed 
CNG of ALK secondary to chromosome 2 polysomy in a significant percentage of breast cancer cases, a phenomenon 
similar to polysomy 17. This study is one of the largest studies to have investigated ALK aberrations in breast cancer 
and the only study to include all subtypes.
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Background
The anaplastic lymphoma kinase (ALK), a gene located on 
the short arm of chromosome 2 (2p23), encodes a trans-
membrane tyrosine kinase receptor capable of activating 
downstream STAT3, AKT/PI3K and RAS/ERK signaling 
pathways responsible for cell proliferation, migration and 
survival (Porter and Vaillancourt 1998; Shaw et al. 2011). 
Alterations in the ALK gene are known to play role in 
genesis and biology of many tumors including anaplas-
tic large cell lymphoma, neuroblastoma, inflammatory 
myofibroblastic tumors, diffuse large B cell lymphoma, 
renal carcinoma, serous carcinoma of the ovary, esopha-
geal squamous cell carcinoma, colon carcinoma and more 
recently non-small cell lung carcinoma. These alterations 
embrace various rearrangements/translocations, somatic 
mutations, copy number gains or amplifications (Hall-
berg and Palmer 2013; Salido et al. 2011; Chen et al. 2008; 
Lamant et al. 2000; Miyake et al. 2002; Cessna et al. 2002; 
Passoni et al. 2009; Dirks et al. 2002; Soda et al. 2007; Li 
et al. 2013). The discovery of the EML4-ALK fusion gene 
in a subset of non-small cell lung carcinoma (3–7 %) has 
steered the development of a therapeutic drug crizotinib 
(a tyrosine kinase inhibitor that inhibits the activity of 
the ALK fusion proteins, cMET, ROS1, and RON) that is 
FDA approved for treating lung cancer patients exhibit-
ing ALK gene rearrangements (Zou et  al. 2007; Kwak 
et al. 2010; Sahu et al. 2013).
A few recent studies have investigated the role of 
ALK aberrations in breast cancer, particularly in the 
context of inflammatory breast cancer and triple nega-
tive breast cancers, however, the results have been 
conflicting (Fukuyoshi et  al. 2008; Lin et  al. 2009; Rob-
ertson et al. 2013; Krishnamurthy et al. 2013; Grob et al. 
2012). Inflammatory breast cancer and triple negative 
breast cancers have the worst prognosis amongst all the 
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subtypes of breast cancer (Engstrøm et al. 2013; Robert-
son et al. 2010). Inflammatory breast carcinoma is a rare 
but aggressive type of locally advanced breast cancer 
characterized by a clinical diagnosis of rapid onset ery-
thema and/or edema of the breast skin (peau d’orange 
appearance) secondary to blockade of dermal lymphat-
ics by tumor emboli. Most inflammatory breast can-
cers are hormone receptor (estrogen and progesterone 
receptors) negative and human epidermal growth factor 
receptor (HER2) positive, and are treated by multidisci-
plinary approaches involving systemic chemotherapy, 
surgery, and radiation. Despite multimodality therapy, 
overall survival is only 35–40 % at 5-years as compared 
to 80 % for non-inflammatory breast cancers (Robertson 
et  al. 2010). Triple negative breast cancer is defined by 
lack of expression of estrogen receptor (ER), progester-
one receptor (PR) and human epidermal growth factor 
receptor (HER2). Due to lack of hormone receptors and 
HER2 overexpression, there is no effective targeted ther-
apy so far for this particular subset of patients. Therefore, 
identification of aberrations in genes such as ALK will be 
clinically useful for breast cancers, given the availability 
of various ALK inhibitors.
The purpose of this study was to determine the inci-
dence and frequency of ALK amplification and rear-
rangements in different breast cancer subtypes including 
triple negative and inflammatory breast cancers.
Methods
Case selection
A database search was performed under the approval 
of our Institutional Review Board for cases meeting 
clinico-pathologic diagnostic criteria for inflamma-
tory breast carcinoma (between 2001 and 2013), triple 
negative breast carcinoma (between 2005 and 2013), 
and other select breast tumor subtypes including ER+, 
Her2+, and triple+ cancers (between 2012 and 2013). 
Slides and formalin fixed paraffin embedded (FFPE) tis-
sue blocks of breast tumors were retrieved from pathol-
ogy archives. Hematoxylin and eosin slides of tumor 
tissue from resection specimens were reviewed and bio-
marker profile was recorded from pathology records. 
American Society of Clinical Oncology (ASCO)/College 
of American Pathologists (CAP) 2010 Guidelines were 
used to score the estrogen, progesterone and HER2 pro-
tein expression.
Tissue microarray
Tissue microarrays (TMA) were constructed with a 
Chemicon International ATA-100 using two representa-
tive 2-mm cores from invasive breast cancers stratified as 
follows: estrogen receptor positive [ER+/PR±/HER2−], 
triple positive [ER+/PR+/HER2+], triple negative [ER−/
PR−/HER2−], HER2 only positive [ER−/PR−/HER2+] 
(Fig. 1).
Fluorescence in‑situ hybridization (FISH) for ALK gene 
rearrangement
FISH studies were performed using ALK break apart probe 
[3′-spectrum orange, 5′-spectrum green] (Empire Genom-
ics, Buffalo, NY, USA) and chromosome 2 centromere 
enumeration probe (CEP2) [spectrum aqua] (Abbott 
Molecular, Des Plaines, IL, USA) in all cases. Three micron 
thick tissue sections were de-paraffinized and pretreated 
using a Dako (Dako, Carpinteria, CA, USA) de-paraffini-
zation and pretreatment technique followed by hybridi-
zation with a probe mixture (ALK and CEP2) of 10 µl at 
45 °C on Hybrite (Abbott Molecular). After hybridization, 
the slides were washed and counterstained with DAPI.
ALK probe validation was carried out on FFPE sec-
tions from non-tumor breast tissue and tonsil tissue. A 
total of 5000 cells were evaluated and scored along with 
the CEP2 [spectrum aqua]. Ninety-seven percent of non-
tumor cells had 2 aqua and 2 ALK fusion signals (yellow), 
the other 3 % showed variations of normal signal patterns 
(Fig. 2). The reference range was determined to be <6 % 
of cells, whereas any abnormal signal pattern in ≥6 % of 
cells was considered abnormal.
FISH analysis
At least 100 tumor cells per case were evaluated in 133 
patients with breast cancer. Low copy number gain 
(LCNG) was defined as 3–6 ALK signals, and high copy 
number gain (HCNG) with >6 ALK signals in ≥6  % of 
tumor cells. Amplification was defined as >6 copies of 
ALK signals with no more than 2 centromere enumera-
tion probe 2 (CEP2) aqua signals in >15 % of cells. Posi-
tive rearrangement was defined if 1 set of orange and 
green signals were >2 signals apart in >15  % of tumor 
cells, or when a single orange signal with a separate 
fusion (shown as one yellow signal) was seen in >15  % 
tumor cells. Two different observers performed evalua-
tions to reduce inter-observer variability.
ALK immunohistochemical staining
Immunohistochemistry for ALK protein was performed 
only in IBC cases, using standard laboratory protocols 
in Dako Autostainer Link 48. The de-paraffinized tissue 
microarray of the IBC cases (n = 13) was pretreated with 
heat-induced epitope retrieval: the slide was pre-heated to 
a temperature of 65 °C; the epitope retrieval temperature 
was 97 °C for 20 min followed by cooling down to 65 °C. 
The slide was then washed into diluted EnVision FLEX 
Wash Buffer at 22  °C for 3  min and then incubated for 
20 min with FLEX mouse monoclonal anti-human CD246 
ALK antibody (clone ALK1, Dako, Carpinteria, CA, USA) 
Page 3 of 6Hanna et al. SpringerPlus  (2015) 4:439 
and FLEX+, mouse, Linker. Positive and negative con-
trols were performed simultaneously. Positive staining was 
defined as brown cytoplasmic positivity in the tumor cells.
Results
The distribution of our 133 study cases is as follows: 
ER+/PR±/HER2− (n = 37), ER−/PR−/HER2+ (n = 15), 
ER−/PR−/HER2− (n = 61), ER+/PR+/HER2+ (n = 20). 
Of these 133 cases, 13 had a clinico-pathologic diagnosis 
of inflammatory breast cancer and include 3 ER−/PR−/
HER2− (24 %), 5 ER−/PR−/HER2+ (38 %), and 5 ER+/
PR±/HER2− (38 %) cases.
None of the 133 cases showed ALK rearrangement 
or amplification. However, copy number gains of ALK 
were identified in 82 of 133 patients (62 %). Of these 82 
cases, four (5  %) demonstrated HCNGs of ALK (range 
6–13 % of tumor cells) and include 1 ER−/PR−/HER2−, 
2 ER+/PR−/HER2− and 1 HER2 only positive (ER−/
PR−/HER2+) case. The remaining 78 cases (95 %) dem-
onstrated low copy number gains and include 12 (80 %) 
ER−/PR−/HER2+ (range 10–68  % of tumor cells), 39 
(64 %) ER−/PR−/HER2− (range 6–68 % of tumor cells), 
21 (57  %) ER+/PR±/HER2− (range 6–69  % of tumor 
cells), and 6 (30  %) ER+/PR+/HER2+ cases (range 
6–91 % of tumor cells) (Table 1).
Since the previous studies on ALK are primarily 
focused on inflammatory breast carcinoma, we analyzed 
the results of our 13 inflammatory breast carcinoma 
cases separately. All 13 cases showed low or HCNGs of 
Fig. 1 Representative tissue microarray. IBC inflammatory breast cancer, HER2 positive [ER−/PR−/HER2+], triple negative [ER−/PR−/HER2−]; triple 
positive [ER+/PR+/HER2+], ER positive [ER+/PR±/HER2−]
Fig. 2 FISH of normal breast terminal duct lobule showing normal 
disomy for ALK [3′-spectrum orange, 5′-spectrum green] signals 
(yellow); a normal pattern in non-tumor breast cells. Inset CEP2 probe 
[spectrum aqua] performed on metaphase and control cells with 
normal 2 signal pattern
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ALK without any rearrangement or amplification. Inter-
estingly 3 of the 4 cases in HCNG cohort were inflamma-
tory breast carcinomas (1 ER−/PR−/HER2− and 2 ER+/
PR−/HER2−; range 6–13 % of tumor cells). The remain-
ing ten cases demonstrated low copy number gains 
(range 9–69 % of tumor cells).
The CEP2 analysis in HCNG cases revealed polysomy 
of chromosome 2 in all 4 (100 %) cases with 3–16 CEP2 
signals noted in 51–64 % of tumor cells (Fig. 3). The CEP2 
analysis in the remaining cases with low copy number 
gains also showed chromosome 2 polysomy (3–8 signals/
cell, range 6–87 % of tumor cells) (Fig. 4).
Immunohistochemical staining for ALK protein 
expression was only performed in the IBC cases (n = 13) 
and none of the cases expressed ALK protein.
Discussion
Our study demonstrated that ALK gene was neither rear-
ranged nor amplified in any of the 133-breast cancer 
cases evaluated by FISH. However, a significant percent-
age of cases (82/133; 62  %) revealed low copy number 
gains of ALK irrespective of the subtype. HCNGs of ALK were limited to a subset of inflammatory breast cancer 
(3, 23  %), and a single ER−/PR−/HER2+ (1, 7  %) case. 
All other tumor subtypes showed only low copy num-
ber gains. The two subtypes with the most copy number 
alterations were the inflammatory breast cancer (100 %) 
and ER−/PR−/HER2+ cases (87  %). FISH testing for 
CEP2 probe demonstrated that increased copy num-
ber gains of ALK are due to polysomy of chromosome 2 
rather than true amplification of ALK gene.
There are very few studies exploring ALK gene aber-
rations in breast cancer, and the results yielded have 
been conflicting. In 2008, Fukuyoshi et  al. used EML4-
ALK transcripts to detect the incidence of EML4-ALK 
rearrangements in lung, colon, and breast cancer. Their 
study did not detect any EML4-ALK rearrangements in 
90 breast cancer cases included in the study (Fukuyoshi 
et al. 2008). Conversely Lin et al. (2009) identified EML4-
ALK rearrangements in 5 of 209 (2.4  %) breast cancers 
(subtype unspecified) using RT-PCR exon array genomic 
sequencing and confirmatory FISH testing. Robertson 
et  al. exclusively studied inflammatory breast cancers 
Table 1 Signal pattern [n (cell range %)] of ALK
1O one orange signal (3′), 1G one green signal (5′), 1F one fusion signal (yellow), LCNG low copy number gains, HCNG high copy number gains
Split pattern (1O1G1F) Single orange (1O1F) LCNG HCNG
ER−/PR−/HER2− (n = 61) 1 (2 %) 12 (1–3 %) 39 (6–68 %) 1 (13 %)
ER−/PR−/HER2+ (n = 15) 0 (0 %) 3 (1–3 %) 12 (10–68 %) 1 (8 %)
ER+/PR±/HER2− (n = 37) 3 (2–3 %) 7 (1–12 %) 21 (6–69 %) 2 (6–11 %)
ER+/PR+/HER2+ (n = 20) 0 (0 %) 1 (1 %) 6 (6–91 %) 0 (0 %)
Inflammatory breast carcinoma (n = 13) 3 (2–3 %) 3 (5–12 %) 10 (9–69 %) 3 (6–13 %)
Fig. 3 High copy number gain and chromosome 2 polysomy. A 
case of inflammatory breast cancer revealing >6 signals/cell of ALK 
break-apart probes (HCNG) in representative tumor cells (closed-head 
arrows). Note, the same tumor cells show >2 CEP2 (aqua) signals, 
indicating polysomy for chromosome 2
Fig. 4 Low copy number gain. A case of HER2+ breast cancer is 
shown revealing 3–6 ALK signals of ALK break-apart probes in repre-
sentative tumor cells (open-head arrows). Normal signal pattern are 
seen in cells (arrowheads), as 2 ALK (yellow) signals with 2 CEP2 (aqua) 
signals
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using Reverse Phase Protein Microarray analysis, a path-
way activation mapping technique, and reported activa-
tion of multiple members of the receptor tyrosine kinase 
ALK signaling network (JAK1/STAT3, AKT, mTOR, PDK-
1 and AMP kinase β) in inflammatory breast cancer cell 
lines, at levels similar to those in ALK rearranged non-
small cell lung cancers. Authors extended their study to 
clinical tumor samples of inflammatory breast cancer and 
detected ALK copy number gains and gene amplification 
in 20/25 (80  %) patient tumor samples. They also iden-
tified one case with an EML4-ALK translocation. Fur-
thermore, these investigators successfully demonstrated 
that even the submicromolar concentrations of crizotinib 
induced significant tumor shrinkage in the pre-clinical 
xenograft models of inflammatory breast cancer. Cur-
rently a phase I clinical trial is enrolling patients with 
inflammatory breast carcinoma for treatment with crizo-
tinib (Robertson et al. 2013). In contrast, Krishnamurthy 
et  al. (2013) did not detect EML4-ALK gene rearrange-
ment or ALK protein expression in the inflammatory 
breast cancer cases. There is only one study published 
to date addressing triple negative breast cancers and did 
not report EML4-ALK rearrangement in 65 cases tested 
using FISH (Grob et  al. 2012). Although the results of 
aforementioned studies are inconsistent, they collectively 
suggest lower incidence of EML4-ALK rearrangements in 
breast cancer as compared to non-small cell lung cancer.
Our study is one of the largest clinical studies to have 
investigated ALK gene rearrangements and amplifica-
tion in breast cancer and the only study to include all 
subtypes. This study highlights that copy number gain 
of ALK gene is the result of polysomy of chromosome 2 
and reflects a common phenomenon in all breast cancer 
subtypes, specifically in inflammatory and ER−/PR−/
HER2+ breast cancers.
The functional significance of ALK copy number gains 
or polysomy2 in breast carcinogenesis is not clear. Recent 
study by Kim et  al. demonstrated that ALK CNG was 
observed in 17/36 (47.2  %) IBC cases and was associ-
ated with worse overall survival when compared to the 
patients without ALK CNG by univariate analysis (24.9 
vs 38.1 months; p = 0.033). The recurrence free survival 
after mastectomy was also shorter in the patients with 
ALK CNG (12.7 vs 43.4  months; p =  0.016) (Kim et  al. 
2015). Studies of ALK in solid tumors other than breast 
have shown similar correlation with worse prognosis. 
Jia et al. (2014) reported that increased ALK copy num-
ber gains in hepatocellular carcinoma are associated 
with a decreased 3-year overall survival (18.2 vs 63.6 %; 
p = 0.021) and 3-year progression free survival (18.2 vs 
46.9  %; p  =  0.019) as compared to those without ALK 
copy number alterations. In lung cancer, copy number 
gain of ALK is a more frequent phenomenon than ALK 
rearrangement, and is reported in up to 63  % of cases 
(Salido et  al. 2011). This has persuaded investigators to 
study if tyrosine kinase inhibitors would be effective even 
in patients with ALK copy number gains without rear-
rangement; however, the results have been conflicting. 
A recent study tested crizotinib sensitivity in nine lung 
cancer cell lines and three patients with NSCLC exhibit-
ing ALK CNG, and concluded that HCNG without ALK 
rearrangement has predictive value for chemo sensitivity 
to crizotinib (Kalai et  al. 2012). On the contrary; CNG 
of ALK has been implicated as one of the mechanisms 
for developing resistance to tyrosine kinase inhibitors. 
Pietrantonio et al. (2014) have reported that gain of ALK 
gene copy number may predict lack of benefit from anti-
EGFR treatment in patients with advanced colorectal 
cancer and RAS-RAF-PI3KCA wild-type status. It would 
be of interest to study whether ALK tyrosine kinase 
inhibitors would be effective in breast cancers with ALK 
copy number gains.
In our study, none of the 13 inflammatory breast cancer 
cases (including 3 cases with high CNG) exhibited ALK 
protein overexpression by immunohistochemistry. This is 
in contrast to the study by Kim et al. (2015) where ALK 
protein expression was demonstrated in 15/27 inflam-
matory breast cancer cases. However, no significant cor-
relation was observed between CNG and ALK protein 
expression. Nine of 14 IBC cases without CNG revealed 
ALK protein expression compared to 6 of 13 cases with 
CNG (p = 0.767).
Conclusion
Neither ALK gene rearrangements nor amplification 
were identified in the 133 breast cancer cases evaluated 
in our study. We observed extra copy numbers of ALK 
as a result of chromosome 2 polysomy in 62 % of breast 
cancer cases. This suggests polysomy of chromosome 2 
is common in breast cancer regardless of the subtype, a 
phenomenon analogous to polysomy 17. The clinical and 
functional significance of  chromosome 2 polysomy and 
extra copy numbers of ALK in breast cancer is yet to be 
elucidated. Larger studies with survival data are needed 
in the context of breast cancer to draw such conclusion.
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